Calling The Ombudsman: Contacts With ANDA Sponsors, Investors On The Upswing
Executive Summary
Although the number of contacts from commercial sponsors and the pharmaceutical industry held steady in 2012, the CDER ombudsman’s office heard from more generic drug manufacturers and investors than in the prior year.
You may also be interested in...
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
Small Companies Turning To CDER Ombudsman For Help With Drug Approvals
While the CDER ombudsman dealt with far fewer complaints overall in 2011 than in 2010 due to administrative changes, smaller companies are increasingly asking for help in certain key areas of drug development.